CYNATA THERAPEUTICS LIMITED +Rule 4.7B
Quarterly report for entities subject to Listing Rule 4.7BIntroduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16
Name of entity | ||
Cynata Therapeutics Limited | ||
ABN | Quarter ended ("current quarter") | |
98 104 037 372 | 31 December 2016 | |
Consolidated statement of cash flows | Current quarter $A'000 | Year to date (6 months) $A'000 | |
1. | Cash flows from operating activities | (1,140) | (1,845) |
1.1 | Receipts from customers | ||
1.2 | Payments for | ||
(a) research and development | |||
(b) product manufacturing and operating costs | - | - | |
(c) advertising and marketing | (82) | (149) | |
(d) leased assets | - | - | |
(e) staff costs | (167) | (285) | |
(f) administration and corporate costs | (249) | (565) | |
1.3 | Dividends received (see note 3) | - | - |
1.4 | Interest received | 8 | 35 |
1.5 | Interest and other costs of finance paid | - | - |
1.6 | Income taxes paid | - | - |
1.7 | Government grants and tax incentives | 1,749 | 1,749 |
1.8 | Other (provide details if material) | - | - |
1.9 | Net cash from / (used in) operating activities | 119 | (1,060) |
- Cash flows from investing activities
Payments to acquire:
property, plant and equipment - -
businesses (see item 10) - -
investments - -
Consolidated statement of cash flows
Current quarter
$A'000
Year to date (6 months)
$A'000
(d) intellectual property
-
-
(e) other non-current assets
-
-
2.2
Proceeds from disposal of:
(a) property, plant and equipment
-
-
(b) businesses (see item 10)
-
-
(c) investments
-
-
(d) intellectual property
-
-
(e) other non-current assets
-
-
2.3
Cash flows from loans to other entities
-
-
2.4
Dividends received (see note 3)
-
-
2.5
Other (provide details if material)
-
-
2.6
Net cash from / (used in) investing
-
-
activities
Cash flows from financing activities
Proceeds from issues of shares
Proceeds from issue of convertible notes
Proceeds from exercise of share options
Transaction costs related to issues of shares, convertible notes or options
Proceeds from borrowings
Repayment of borrowings
Transaction costs related to loans and borrowings
Dividends paid
Other (provide details if material)
3.10 Net cash from / (used in) financing activities
- Net increase / (decrease) in cash and cash equivalents for the period
Cash and cash equivalents at beginning of quarter/year to date
Net cash from / (used in) operating activities (item 1.9 above)
Net cash from / (used in) investing activities (item 2.6 above)
Net cash from / (used in) financing activities (item 3.10 above)
3,706 4,866
119 (1,060)
- -
10 10
Consolidated statement of cash flows
Current quarter
$A'000
Year to date (6 months)
$A'000
4.5
Effect of movement in exchange rates on cash held
79
98
4.6
Cash and cash equivalents at end of quarter
3,914
3,914
5.
Reconciliation of cash and cash equivalents
at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts
Current quarter
$A'000
Previous quarter
$A'000
5.1
Bank balances
3,914
3,706
5.2
Call deposits
-
-
5.3
Bank overdrafts
-
-
5.4
Other (provide details)
-
-
5.5
Cash and cash equivalents at end of quarter (should equal item 4.6 above)
3,914
3,706
Current quarter
$A'000
361
-
- Payments to directors of the entity and their associates
Aggregate amount of payments to these parties included in item 1.2
Aggregate amount of cash flow from loans to these parties included in item 2.3
Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2
Directors' fees, salaries including superannuation benefits and professional consultancy fees. All payments are on normal commercial terms.
Current quarter
$A'000
-
-
- Payments to related entities of the entity and their associates
Aggregate amount of payments to these parties included in item 1.2
Aggregate amount of cash flow from loans to these parties included in item 2.3
Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2
-
Total facility amount at quarter end
$A'000
Amount drawn at quarter end
$A'000
-
-
-
-
-
-
- Financing facilities available Add notes as necessary for an understanding of the position
Loan facilities
Credit standby arrangements
Other (please specify)
Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.
-
9.
Estimated cash outflows for next quarter
$A'000
9.1
Research and development
2,440
9.2
Product manufacturing and operating costs
-
9.3
Advertising and marketing
39
9.4
Leased assets
-
9.5
Staff costs
123
9.6
Administration and corporate costs
138
9.7
Other (provide details if material)
-
9.8
Total estimated cash outflows
2,740
10.
Acquisitions and disposals of business entities
(items 2.1(b) and 2.2(b) above)
Acquisitions
Disposals
10.1
Name of entity
-
-
10.2
Place of incorporation or registration
-
-
10.3
Consideration for acquisition or disposal
-
-
10.4
Total net assets
-
-
10.5
Nature of business
-
-
-
- 10
-
-
-
-
-
-
-
- 10
-
-
-
-
-
-
10
10
Cynata Therapeutics Ltd. published this content on 25 January 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 25 January 2017 08:26:08 UTC.
Original documenthttp://cynata.com/wp-content/uploads/2017/01/17.01.25.Appendix-4C.pdf
Public permalinkhttp://www.publicnow.com/view/A2D0AE3527BF96D79D5DD677E786B2AFBABDD0A4
